Floatz logo

Trastuzumab Imbotolimod

HER2-positive Endometrial Cancer

Bolt Biotherapeutics, Inc.antibody_drug_conjugatePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

234 Active assets in the HER2-positive Endometrial Cancer cohort.

Asset / SponsorPhaseRating
Indocyanine Green
Istanbul University
Phase 4BB
Inno-206
AstraZeneca
Phase 3BB
Palbociclib
University Medical Center Groningen
Phase 4BB
Olaparib
Qilu Pharmaceutical Co., Ltd.
Phase 4BB
FILGRASTIM
Mayo Clinic
Phase 3B

View all 50 →

Same molecule, other indications

Trastuzumab Imbotolimod is also rated in:

HER2 positive breast carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
51 / 100
View asset →
gastroesophageal cancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →